The effect of vildagliptin versus metformin on hepatic steatosis in type 2 diabetic patients: a randomized controlled trial

Asmaa S. Mohamed, Hosam M. Ahmad, Mohammed A. Sharawy, Fatma M. M. Kamel · 2024

Read The effect of vildagliptin versus metformin on hepatic steatosis in type 2 diabetic patients: a randomized controlled trial by Asmaa S. Mohamed, Hosam M. Ahmad, Mohammed A. Sharawy, Fatma M. M. Kamel (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11645785.txt.

Description

Asmaa Mohamed, Hosam Ahmad, Mohammed Sharawy, and Fatma Kamel compare two common diabetes drugs for their effect on fatty liver in people with type 2 diabetes. Fatty liver, or hepatic steatosis, is common in these patients, and some diabetes drugs may help it. The trial enrolled 246 patients who were newly diagnosed.

Patients were assigned at random to vildagliptin or to metformin for six months. Both groups improved in blood sugar control, weight, body measures, and liver fat scores, judged by an index and by ultrasound. Metformin cut weight and body mass index by more. Ultrasound showed no clear difference between the drugs in liver fat relief. Blood fat values, above all total cholesterol and LDL, predicted fatty liver best. The authors conclude both drugs help the liver, with metformin ahead on weight.

Catalog record

CREATORAsmaa S. Mohamed, Hosam M. Ahmad, Mohammed A. Sharawy, Fatma M. M. Kamel
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11645785

Browse the full library · About the Tower of Babel